Company
Emmaus Life Sciences Inc
OTCMKTS: EMMA
Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets U.S. Food and Drug Administration approved Endari® (L-glutamine oral powder) indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as diverticulosis. For more information, please visit www.emmausmedical.com .
27 stories · page 1 of 2
Emmaus Life Sciences receives first major purchase order in Saudi Arabia
Sickle cell disease treatment company also receives registration certificate from Qatar Ministry of Public Health
Emmaus Life Sciences says Q3 revenue boosted by sales of Endari in the United Arab Emirates
"We enjoyed a third straight substantial increase in quarterly net revenue due to increased sales in the Middle East North Africa region," said Yutaka Niihara, Emmaus’ chairman and CEO
Emmaus Life Sciences announces collaboration with Kier (Junior) Spates to educate and support patients with sickle cell disease
“Our collaboration with Mr Spates will help destigmatize SCD and inform 9 million weekly listeners to Mr Harvey’s popular show, including those with SCD, about Endari,” said Emmaus CEO Yutaka Niihara
Emmaus Life Sciences reports Q2 2022 net revenue of $4.3M after sales of Endari sickle cell disease treatment to United Arab Emirates
CEO Yutaka Niihara said the company is "looking forward to continued increases in sales in the Middle East North Africa region, where we are anticipating a decision on our marketing approval application for Endari in the Kingdom of Saudi Ar
Emmaus Life Sciences says it successfully expands market access to sickle cell treatment Endari in 1Q
“After the United Arab Emirates, granted full marketing authorization in March, we received a significant order from one of our distributors in the country and expect to see a continuing flow of orders,” said Emmaus CEO Yutaka Niihara
Emmaus Life Sciences launches full-service telehealth solution with online access to sickle cell treatment Endari
“As the telehealth solution grows, we are optimistic that it will help us to reach new patients and add meaningful revenue for Emmaus," said chairman and CEO Yutaka Niihara
Emmaus Life Sciences presents positive study data on Endari treatment in sickle cell patients
Data showed that statistically, sickle cell patients treated with Endari had significantly fewer vaso-occlusive events and hospitalizations through 72 weeks’ follow-up versus baseline
Emmaus Life Sciences says it is making progress in expanding access to Endari as it reports FY2021 revenue of $20.6M
Emmaus Life Sciences CEO Yutaka Niihara told investors that the 2022 year is shaping up to be “an exciting one” as the company expands its clinical pipeline
Emmaus Life Sciences says its Endari sickle cell treatment to be added to Florida Medicaid’s preferred drug list
"This moves us another step closer to our goal of making Endari readily available to all professional health care providers and their sickle cell disease patients in need," said company chairman and CEO Yutaka Niihara
Emmaus Life Sciences wins marketing authorization for Endari in United Arab Emirates
The company estimates that as many as 600 sickle cell disease patients live or work in the UAE with about 225,000 patients throughout the Middle East-North Africa region who could potentially be treated with Endari